Berberine Improves Cancer-Derived Myocardial Impairment in Experimental Cachexia Models by Targeting High-Mobility Group Box-1
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25094735 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Kei Goto und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Nara, Japan. Hauptthemen laut MEDLINE: Berberine, Cachexia, HMGB1 Protein. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Culture, Sports, Science and Technology, MEXT KAKENHI.
Themen: Mobilisation
Abstract (Originalsprache)
Cardiac disorders in cancer patients pose significant challenges to disease prognosis. While it has been established that these disorders are linked to cancer cells, the precise underlying mechanisms remain elusive. In this study, we investigated the impact of cancerous ascites from the rat colonic carcinoma cell line RCN9 on H9c2 cardiomyoblast cells. We found that the ascites reduced mitochondrial volume, increased oxidative stress, and decreased membrane potential in the cardiomyoblast cells, leading to apoptosis and autophagy. Although the ascites fluid contained a substantial amount of high-mobility group box-1 (HMGB1), we observed that neutralizing HMGB1 with a specific antibody mitigated the damage inflicted on myocardial cells. Our mechanistic investigations revealed that HMGB1 activated both nuclear factor κB and phosphoinositide 3-kinases-AKT signals through HMGB1 receptors, namely the receptor for advanced glycation end products and toll-like receptor-4, thereby promoting apoptosis and autophagy. In contrast, treatment with berberine (BBR) induced the expression of miR-181c-5p and miR-340-5p while suppressing HMGB1 expression in RCN9 cells. Furthermore, BBR reduced HMGB1 receptor expression in cardiomyocytes, consequently mitigating HMGB1-induced damage. We validated the myocardial protective effects of BBR in a cachectic rat model. These findings underscore the strong association between HMGB1 and cancer cachexia, highlighting BBR as a promising therapeutic agent for myocardial protection through HMGB1 suppression and modulation of the signaling system.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Nara, Japan.
- Pathology Laboratory, Research Institute, Tokushukai Nozaki Hospital, 2-10-50 Tanigawa, Daito 574-0074, Osaka, Japan.
ORCID-Profile: Hiroki Kuniyasu
Förderung
- Ministry of Education, Culture, Sports, Science and Technology
- MEXT KAKENHI
Zitieren
APA
Goto, K., Fujiwara-Tani, R., Nukaga, S., Miyagawa, Y., Kawahara, I., Nishida, R., Ikemoto, A., Sasaki, R., Ogata, R., Kishi, S., Luo, Y., Fujii, K., Ohmori, H., & Kuniyasu, H. (2024). Berberine Improves Cancer-Derived Myocardial Impairment in Experimental Cachexia Models by Targeting High-Mobility Group Box-1. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25094735
Vancouver
Goto K, Fujiwara-Tani R, Nukaga S, Miyagawa Y, Kawahara I, Nishida R, et al. Berberine Improves Cancer-Derived Myocardial Impairment in Experimental Cachexia Models by Targeting High-Mobility Group Box-1. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25094735
BibTeX
@article{Goto2024,
author = {Goto, Kei and Fujiwara-Tani, Rina and Nukaga, Shota and Miyagawa, Yoshihiro and Kawahara, Isao and Nishida, Ryoichi and Ikemoto, Ayaka and Sasaki, Rika and Ogata, Ruiko and Kishi, Shingo and Luo, Yi and Fujii, Kiyomu and Ohmori, Hitoshi and Kuniyasu, Hiroki},
title = {Berberine Improves Cancer-Derived Myocardial Impairment in Experimental Cachexia Models by Targeting High-Mobility Group Box-1},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25094735}
}
EUVIMED